|
WO2019059817A1
|
|
Vaccine based on fusion protein and plasmid dna
|
|
RU2711111C1
|
|
Hybrid protein igf-1-long for treating stroke, nucleic acid, vector, cell, pharmaceutical composition, method of treatment
|
|
US2019367449A1
|
|
Phenylcreatine, its use and method for its production
|
|
EA034521B1
|
|
Escherichia coli bacteria strain - human il-17a producer
|
|
EA036780B1
|
|
Plasmid dna encoding beta-endorphin, bacterial producer, analgesic agent
|
|
RU2721282C2
|
|
Method for treating multiple sclerosis (versions)
|
|
EA035207B1
|
|
Strain of escherichia coli bl21 (de3)/pet-21a(+) bacteria - producer of predominantly monomeric somatotropine
|
|
RU2611685C2
|
|
Humanized monoclonal antibody specific to syndecan-1
|
|
RU2615440C2
|
|
Fusion protein, dna, genetic construct, recombinant cell, fusion protein-based vaccine for tuberculosis prevention and treatment (versions)
|
|
RU2597789C2
|
|
Analgetic agent on the basis of plasmid dna coding hnp-1, or hnp-2, or hnp-3 (versions)
|
